Canada Life’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-8,272
| Closed | -$427K | – | 2416 |
|
|
2022
Q3 | $427K | Buy |
8,272
+5,656
| +216% | +$234K | ﹤0.01% | 1717 |
|
|
2022
Q2 | $65K | Hold |
2,616
| – | – | ﹤0.01% | 2004 |
|
|
2022
Q1 | $70K | Hold |
2,616
| – | – | ﹤0.01% | 2083 |
|
|
2021
Q4 | $95K | Sell |
2,616
-641
| -20% | -$22.5K | ﹤0.01% | 2021 |
|
|
2021
Q3 | $56K | Hold |
3,257
| – | – | ﹤0.01% | 2207 |
|
|
2021
Q2 | $44K | Hold |
3,257
| – | – | ﹤0.01% | 2311 |
|
|
2021
Q1 | $166K | Buy |
3,257
+420
| +15% | +$25.3K | ﹤0.01% | 1995 |
|
|
2020
Q4 | $175K | Hold |
2,837
| – | – | ﹤0.01% | 1997 |
|
|
2020
Q3 | $155K | Hold |
2,837
| – | – | ﹤0.01% | 1951 |
|
|
2020
Q2 | $162K | Hold |
2,837
| – | – | ﹤0.01% | 1954 |
|
|
2020
Q1 | $115K | Hold |
2,837
| – | – | ﹤0.01% | 1949 |
|
|
2019
Q4 | $111K | Buy |
+2,837
| New | +$49.8K | ﹤0.01% | 2053 |
|
|
2019
Q3 | – | Sell |
-5,527
| Closed | -$52K | – | 2498 |
|
|
2019
Q2 | $52K | Buy |
+5,527
| New | +$64K | ﹤0.01% | 2430 |
|
Other funds holding CCXI
Canada Life's CCXI Position: Q4 2022 in Review
Canada Life sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 8,272 shares — an estimated $427K sold.
Canada Life first reported a position in CCXI in Q2 2019 and held it in 13 quarters. The position peaked at $427K in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Canada Life reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Canada Life sold 8,272 ChemoCentryx, Inc. shares in Q4 2022, an estimated $427K.
- Canada Life first reported a position in ChemoCentryx, Inc. in Q2 2019 and held it in 13 quarters.
- Canada Life's ChemoCentryx, Inc. position peaked at $427K in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Canada Life's 13F filing for Q4 2022, filed 10 Feb 2023.